Alzheon
Last updated: August 29, 2025

Martin Tolar - Founder, President & CEO
USA | Funding: $366.2M (+)
Website: http://www.alzheon.com/
Alzheon is committed to developing innovative medicines for patients suffering from Alzheimer's disease and other neurological and psychiatric disorders. Our Alzheon’s drug development platform which comprises proprietary chemistries, robust clinical efficacy and safety datasets in patients and genetically-defined subpopulations, and the ability to optimize molecules to have the desired therapeutic attributes.
Website: http://www.alzheon.com/
Alzheon is committed to developing innovative medicines for patients suffering from Alzheimer's disease and other neurological and psychiatric disorders. Our Alzheon’s drug development platform which comprises proprietary chemistries, robust clinical efficacy and safety datasets in patients and genetically-defined subpopulations, and the ability to optimize molecules to have the desired therapeutic attributes.

